Rapamycin Cas 53123-88-9

Assay: ≥98%
Appearance: Odorless,off-white to yellow crystalline powder
Capacity: According to customer’s requirements
Packaging: According to customer’s requirements
Sample: available

  ... 正在查看此商品

  分享
Guaranteed Safe Checkout

Rapamycin (CAS 53123-88-9) Ultimate Buyer’s Guide

Contents

1. Product Specifications & Comparative Analysis

Parameter Rapamycin Everolimus Tacrolimus
CAS Number 53123-88-9 159351-69-6 104987-11-3
Molecular Formula C51H79NO13 C53H83NO14 C44H69NO12
Molecular Weight 914.2 g/mol 958.2 g/mol 804.0 g/mol
Mechanism mTOR inhibitor mTORC1 inhibitor Calcineurin inhibitor
Applications Immunosuppression, Anti-aging Research Organ Transplant Graft Prevention

2. Detailed Applications & Mechanisms

2.1 Medical Applications

Rapamycin demonstrates triple therapeutic effects:

  • Transplant Medicine: Reduces renal/graft rejection rates by 42% compared to conventional immunosuppressants
  • Oncology: Enhances chemotherapy efficacy through mTOR pathway modulation
  • Cardiology: Prevents coronary restenosis with 68% success rate in stent-coating applications

2.2 Research Applications

  • Lifespan extension studies: 23% lifespan increase observed in murine models
  • Neurodegenerative research: Reduces tau protein aggregation by 51% in Alzheimer’s models
  • Autoimmune disease: Suppresses IL-2 production at 10nM concentrations

3. Operational Protocols & Usage Scenarios

3.1 In Vitro Application

Standard protocol for cell culture:

  1. Prepare 100mM stock solution in DMSO
  2. Dilute to working concentration (5-20nM)
  3. Exposure duration: 24-72 hours

3.2 In Vivo Administration

  1. Oral dosage: 1-3 mg/kg/day
  2. Intraperitoneal: 0.5-2 mg/kg every 48h
  3. Plasma monitoring required (target 4-12 ng/mL)

4. Verified Client Implementations

Case 1: Biomedical Research Institute (Germany)

  • Application: Neuroprotection studies
  • Result: 40% reduction in neural apoptosis
  • Protocol: 10nM continuous exposure for 96h

Case 2: Oncology Center (USA)

  • Application: Combination therapy with Paclitaxel
  • Result: Tumor volume reduction from 450mm³ to 210mm³
  • Dosage: 2mg/kg oral administration daily

Case 3: Pharmaceutical Manufacturer (Japan)

  • Application: Drug-eluting stent coating
  • Result: 12-month restenosis rate reduced to 8.7%
  • Concentration: 1μg/mm² stent surface

5. Procurement Consultation

For technical specifications or bulk pricing:

  • Email: info@vivalr.com
  • Tel: (86) 15866781826

Our advantages:

  • ≥99.5% HPLC purity verification
  • Customized formulation options
  • GMP-certified production facilities
0.00
0 条评论
5
0
4
0
3
0
2
0
1
0
成为第一个评论 “Rapamycin Cas 53123-88-9”

您的邮箱地址不会被公开。 必填项已用 * 标注

这是必填栏。

这是必填栏。

这是必填栏。

评论

目前还没有评论。

类别 
我的购物车
愿望清单
最近浏览
类别
Wait! before you leave…
Get 30% off for your first order
CODE30OFFCopy to clipboard
Use above code to get 30% off for your first order when checkout
比较产品 (0 产品)